Table 4.

Univariate and multivariate survival analyses in relation to MGB-2 and clinical parameters.

	OS				DFS				PFS
Variables	N	HR	95% CI	p	N	HR	95% CI	p	N	HR	95% CI	p
Univariate analysis
MGB-2mRNA RQ
high vs medium & low	98	0.45	0.22–0.87	0.016	69	0.15	0.05–0.37	< 0.001	94	0.36	0.17–0.69	0.002
MGB-2 immunostaining
1+ vs 0	106	0.47	0.24–0.87	0.015	75	0.28	0.12–0.58	< 0.001	102	0.43	0.22–0.77	0.004
Age
> 40 vs ≤ 40	106	1.98	0.77–7.23	0.172	75	2.51	0.84–12.27	0.107	102	1.72	0.73–5.28	0.234
FIGO stage
≤ IIB vs >IIB	106	0.06	0.007–0.24	< 0.001	75	0.13	0.03–0.35	< 0.001	102	0.05	0.006–0.20	< 0.001
Residual tumor
TR ≥ 0.5 vs TR = 0	106	4.62	2.31–10.41	< 0.001	75	2.34	1.22–4.69	0.010	102	4.11	2.17–8.54	< 0.001
Presence of ascites
yes vs no	106	2.64	1.44–5.13	0.001	75	2.66	1.37–5.45	0.003	102	2.52	1.42–4.70	0.001
Lymph nodes
positive vs negative	82	2.93	1.42–6.13	0.004	65	2.93	1.44–5.89	0.004	82	2.43	1.27–4.62	0.008
Grade
G2&G3 vsG1	106	2.95	0.79–26.15	0.118	75	3.04	0.81–27.08	0.110	102	3.17	0.86–28.01	0.092
Preoperative CA125 serum level
≥ Threshold vs < Threshold*	103	2.80	0.95–13.62	0.064	74	4.87	1.30–43.35	0.014	99	3.15	1.07–15.30	0.035
Multivariate analysis**
A.
MGB-2mRNA RQ
high vs medium & low	106	0.79	0.38–1.62	0.52	75	0.25	0.08–0.75	0.014	102	0.63	0.30–1.31	0.22
B.
MGB-2 immunostaining
1+ vs 0	106	1.02	0.51–2.04	0.96	75	0.41	0.17–0.995	0.048	102	0.89	0.46–1.73	0.76

Abbreviations: HR, hazard ratio; CI, confidence interval of the estimated HR.

*Threshold = 200 U/ml for pre-menopausal patients & 35 U/ml for post-menopausal patients.

**Multivariate models were adjusted for stage of disease, grade, age, presence of ascites, residual tumor and lymphatic involvement. Multiple imputation data.